Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.

Research output: Contribution to journalArticlepeer-review

76 Citations (SciVal)

Abstract

Summary. The bypassing agents factor eight inhibitor bypassing activity (FEIBA) anti-inhibitor coagulant complex and recombinant activated factor VII (rFVIIa) have been established as safe and effective therapies for treating bleeding episodes in haemophilia patients with inhibitors. However, the efficacy of each bypassing agent can vary, and neither agent is universally effective. The reasons for such variability have yet to be confirmed, but may involve patient-specific factors and the mechanisms of action (MOAs) and pharmacokinetic profiles of these two agents. This issue underscores the necessity of both products in the comprehensive care of patients with haemophilia and inhibitors. The objective of this review is to discuss the evidence of a differential haemostatic response to bypassing agents and the potential roles of MOA and patient-specific factors in contributing to the differences in response.
Original languageEnglish
Pages (from-to)41343
JournalHaemophilia
Volume15
DOIs
Publication statusPublished - 2009

Subject classification (UKÄ)

  • Hematology

Fingerprint

Dive into the research topics of 'Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.'. Together they form a unique fingerprint.

Cite this